Protocol List

The Protocol List provides a listing of NCI clinical trials that are supported by the CTSU and are either active, near activation or temporarily closed. The list may be sorted by Protocol Number, Lead Organization, NIH Program, Status, or Phase. Clicking to the right of each title in the header row will display an arrow, an upwards facing arrow will sort by ascending order and a downwards facing arrow will display by descending order. Each protocol number is hyperlinked and clicking on the protocol number will open a new website, the National Cancer Institute’s Clinical Trials Physicians Data Query (PDQ®). PDQ provides additional information about each clinical trial including the trial summary, eligibility criteria and a listing of sites that have the trial open. The protocol list can be exported to and Excel or CSV file or printed by selecting the icon located above the header row.

*Some accruals have occurred outside of the CTSU systems and are collected manually, thus the total accrual number may not be accurate.
#Protocol NumberLead OrganizationNIH ProgramDiseaseStatusProtocol TitlePhaseAccrual TargetAccrual Total
  • First Page
  • Previous Page
  • Page 1 of 5
  • Next Page
  • Last Page
  • Last update: 3:02:37 PM UTC
1EAY131-Z1EECOG-ACRINNCTNN/AActiveMATCH Treatment Subprotocol Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions00
2EAY131-MECOG-ACRINNCTNN/AActiveMATCH Treatment Subprotocol M: Phase II Study of MLN0128 (Tak-228) in Patients with Tumors with TSC1 or TSC2 Mutations00
3EAY131-GECOG-ACRINNCTNN/AActiveMATCH Treatment Subprotocol G: Phase II Study of Crizotinib in Patients with ROS1 Translocations (Other Than Patients with Non-Small Cell Lung Cancer)00
4N0577ALLIANCENCTNCNS Cancer (Primary tumor)ActiveN0577 (CODEL): Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade GliomaIII361133
5RTOG-0724NRGNCTNFemale Reproductive System CancerActivePhase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical HysterectomyIII285178
6GOG-0263NRGNCTNFemale Reproductive System CancerActiveRandomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)III534284
7EAY131-S2ECOG-ACRINNCTNN/AActiveMATCH Treatment Subprotocol S2: Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 Mutations00
8GOG-0238NRGNCTNFemale Reproductive System CancerActiveA Randomized Trial of Pelvic Irradiation with or Without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine CorpusII210137
9E2906ECOG-ACRINNCTNLeukemiaTemporarily Closed to AccrualPhase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)III747727
10RTOG-0924NRGNCTNMale Reproductive System CancerActiveAndrogen Deprivation Therapy and High Dose Radiotherapy with or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized TrialIII25802197
11RTOG-1119NRGNCTNBreast CancerActivePhase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination with Concurrent Lapatinib in Patients with Brain Metastasis From HER2-Positive Breast Cancer: A Collaborative Study of NRG Oncology and KROGII143127
129775LAO-MN026ETCTNLeukemiaActiveA Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)II3515
13S1512SWOGNCTNSkin CancerActive A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)II7712
149910LAO-11030ETCTNLung, Mediastinal, and Pleural CancerActiveA Phase 1 Trial of MLN0128 (TAK-228) in Combination with Osimertinib (AZD9291) in Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) After Progression on a Previous EGFR Tyrosine Kinase InhibitorI3612
15EA8143ECOG-ACRINNCTNKidney CancerActiveA Phase 3 RandOmized Study Comparing PERioperative Nivolumab Vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)III76681
169979LAO-MN026ETCTNMiscellaneous and Metastatic CancerActivePhase 1 and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2-Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain MetastasesI474
179767LAO-CT018ETCTNUrothelial/ Bladder CancerActiveAn Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 MutationII2096
189984LAO-CT018ETCTNMale Reproductive System CancerActiveA Randomized Phase 2 Study of Cediranib in Combination with Olaparib Versus Olaparib Alone in Men with Metastatic Castration Resistant Prostate CancerII9044
19A221502ALLIANCENCORPLung, Mediastinal, and Pleural CancerActivePulmonary Rehabilitation Before Lung Cancer ResectionIII1945
2010005LAO-NCIETCTNSoft Tissue Cancer/SarcomaActiveA Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part SarcomaII2619
2110031LAO-MA036ETCTNBreast Cancer;Female Reproductive System Cancer;Miscellaneous and Metastatic CancerActiveA Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors with Expansion in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast CancerI4011
22S1616SWOGNCTNSkin CancerActiveA Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 AgentII9419
23EAF151ECOG-ACRINNCTNCNS Cancer (Primary tumor)ActiveChange in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent GlioblastomaII16514
2410013LAO-NC010ETCTNBreast CancerActiveRandomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, with or Without Atezolizumab in Triple Negative Breast Cancer (TNBC)II6041
25EAY131-K2ECOG-ACRINNCTNN/AActiveMATCH Treatment Subprotocol K2: Phase 2 Study of Erdafitinib (JNJ-42756493) in Patients with Tumors with FGFR Mutations and Fusions00
26EAY131-TECOG-ACRINNCTNN/AActiveMATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations00
27S1400SWOGNCTNLung, Mediastinal, and Pleural CancerActiveA Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)II/III100001721
28A081105ALLIANCENCTNLung, Mediastinal, and Pleural CancerActiveRandomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)III450214
29A151216ALLIANCENCTNLung, Mediastinal, and Pleural CancerActiveAdjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)Other83003424
30A091305ALLIANCENCTNEndocrine CancerActiveA Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination with Paclitaxel in Patients with Advanced Anaplastic Thyroid CancerII5013
31EA8134ECOG-ACRINNCTNMale Reproductive System CancerActiveInPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)III2006
32NRG-GI003NRGNCTNGastrointestinal CancerActiveA Phase III Randomized Trial of Protons Versus Photons for Hepatocellular CarcinomaIII1677
3310026LAO-MA036ETCTNLeukemiaActiveA Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid LeukemiaI4812
34NRG-BR005NRGNCTNBreast CancerActiveA Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response After Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without SurgeryII17544
35EA1151ECOG-ACRINNCORPBreast CancerActiveTomosynthesis Mammographic Imaging Screening Trial (TMIST)III1649462779
369974EDDO-NY011MISCELLANEOUSLung, Mediastinal, and Pleural CancerTemporarily Closed to AccrualA Phase II Study of Olaparib Plus Cediranib in Combination with Standard Therapy for Small Cell Lung CancerII1329
3710009LAO-CT018ETCTNLeukemiaActiveA Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination with the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients with Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy FailureI275
3810042LAO-CT018ETCTNLung, Mediastinal, and Pleural CancerActiveA Phase II Trial of AZD9291 (Osimertinib) with or without Bevacizumab in Patients with EGFR Mutation Positive NSCLC and Brain MetastasesII981
3910030LAO-MD017ETCTNLeukemiaActiveA Phase 1 Study of Blinatumomab in Combination with Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients with Poor-Risk, Relapsed or Refractory CD19+ Precursor B-Lymphoblastic LeukemiaI307
4010015EDDO-MI014MISCELLANEOUSSoft Tissue Cancer/SarcomaActiveA Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid HemangioendotheliomaII2718
419608LAO-MN026ETCTNGastrointestinal Cancer;Miscellaneous and Metastatic CancerActiveA Phase I Trial of ABT-263 (Navitoclax), a Bcl-2 Inhibitor, and Sorafenib (Nexavar) in Patients with Relapsed or Refractory Solid Organ TumorsI4420
42CITN-07-FLT3LCITNMISCELLANEOUSSkin CancerTemporarily Closed to Accrual &TreatmentA Phase II, Open-Label, Multicenter, Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 LigandII10060
43NSABP-B-55NRGNCTNBreast CancerActiveA Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant ChemotherapyIII1500178
4410021LAO-MA036ETCTNGastrointestinal Cancer;Lung, Mediastinal, and Pleural CancerActiveA Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination with High or Low-Dose Radiation in Metastatic Colorectal and NSCLCII18054
45NRG-GY009NRGNCTNFemale Reproductive System CancerActiveA Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian CancerII/III48850
46A041501ALLIANCENCTNLeukemiaActiveA Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALLIII3246
47NRG-LU002NRGNCTNLung, Mediastinal, and Pleural CancerActiveMaintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III TrialII/III30011
48ADVL1622COGNCTNBone Cancer;Endocrine Cancer;Gastrointestinal Cancer;Kidney Cancer;Miscellaneous and Metastatic Cancer;Soft Tissue Cancer/SarcomaActivePhase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare TumorsII14671
49AALL15P1COGNCTNLeukemiaActiveA Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene RearrangementPilot11644
50A191402CDALLIANCENCORPMale Reproductive System CancerActiveTesting Decision Aids to Improve Prostate Cancer Decisions for Minority MenIII17283